Velcade hits barricade in EU approval for relapsed NHL
This article was originally published in Scrip
Janssen-Cilag (Johnson & Johnson) has withdrawn its supplemental EU filing for Velcade (bortezomib) in non-Hodgkin's lymphoma after the EMA's advisory group, the CHMP, indicated that the data in the application do not support approval.
You may also be interested in...
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.
Executives On The Move: TG Therapeutics Brings Aboard Pioneering Academic Scientist for Its C-Suite, Roche Decides On A Research Exec And Ascendis Announces A New Global Officer
TG Therapeutics, developing treatments for B-cell malignancies, adds an authority in lymphoma as CSO, and Roche hires a Broad Institute exec to head up Genentech’s research and early development. Plus, Ascendis Pharma, with programs in endocrinology/oncology, picks a global chief commercial officer.